Beyond the known: prospective research directions for the gut-brain axis in obesity and type 1 diabetes mellitus

This letter engages with the seminal review by Argyrakopoulou et al. Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita? Curr Obes Rep, https://doi.org/10.1007/s13679-025-00654-8IF:11.0Q1B1 . on the putative role of the gut-brain axis in the rising prevalence of obesity within type 1 diabetes mellitus (T1DM). We aim to commend the authors while proposing key future research avenues to advance the field from correlation to causation and therapeutic application. We also seek to integrate recent high-impact evidence to contextualize our perspectives. First, we emphasize the need for deep mechanistic studies using gnotobiotic models and targeted metabolomics to delineate the causal role of specific microbial metabolites, informed by recent concepts of host genetic regulation of the gut-liver axis (e.g., via p53/PI3K/AKT/Wnt signaling) and microbiota composition in metabolic disease pathophysiology (1, 2). Second, we highlight the imperative for longitudinal cohort studies to determine the temporal relationship between gut dysbiosis, autoimmunity, and subsequent metabolic complications. Finally, we discuss the promising intersection of microbiome science with emerging therapeutics, including next-generation probiotics and GLP-1 receptor agonists, whose efficacy may be partly mediated through the gut-brain axis. By addressing these priorities and integrating recent knowledge, the scientific community can translate this compelling paradigm into tangible clinical benefits for patients with T1DM.